

PAT up 12% (1st Quarter FY 2019, Consolidated Results)

Mumbai, 31st July, 2018: Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June, 2018.

Q1 FY 2019 performance highlights (compared to Q1 FY 2018)

- Income from operations at Rs. 511 cr. against Rs. 473 cr., up 8%.
- EBITDA at Rs. 157 cr. against Rs. 127 cr., up 24%; EBITDA at 31% of revenue.
- Profit after tax at Rs. 106 cr., against Rs. 95 cr., up 12%; PAT at 21% of revenue.

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said:

“We are pleased with our Q1 performance which is in line with our expectations. Branded generic business in India and Export markets posted healthy growths. Despite challenging pricing environment in USA, we have posted healthy growth for the quarter.

Going forward, branded generic business in India & Emerging Markets; and generic business in USA will be key focus markets for us.”

India

For Q1 FY 2019, India sales was Rs. 178 cr. (against Rs. 143 cr.) posting growth of 24%.

As per IMS MAT June 2018, we have posted healthy growth of 10% in Cardiology (segment growth of 7%), 11% in Ophthalmology (segment growth of 7%), de-growth of 1% in Dermatology (segment growth of 14%) and 12% in Pain Management (segment growth of 5%).

Exports

During Q1 FY 2019, total export sales were Rs. 324 cr. (against Rs. 321 cr.) posting growth of 1%.

Emerging Market branded generic sales was Rs. 209 cr. (against Rs. 169 cr.) posting 23% growth.

- Africa branded generic sales was Rs. 77 cr. (against Rs. 71 cr.) posting 9% growth
- Asia branded generic sales was Rs. 129 cr. (against Rs. 96 cr.) posting 35% growth

Africa Institution sales was Rs. 54 cr. (against Rs. 97 cr.) posting 44% de-growth. This de-growth was due to increased competition, pricing pressure and lower procurements.

US generic sales was Rs. 61 cr. (against Rs. 54 cr.) posting 13% growth.

In US, during Q1 FY 2019, we received 1 ANDA final approval, 2 tentative approvals and filed 1 ANDA with US FDA. Out of 20 final ANDA approvals, we have commercialized 18 products. We hold 4 tentative approvals and 16 ANDAs are awaiting US FDA approval. Company plans to file 10-12 ANDAs during this financial year.

R&D

During Q1 FY 2019, R&D expenses were Rs. 41 cr., (Q1 FY 2018 Rs. 42 cr.) which is 8% of operating revenue.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai, having a team of 850+ scientists. Company has 7 world class manufacturing facilities located in India and Mauritius.

For last 5 financial years, company has posted healthy performance with its consolidated total income growing at 15% CAGR and net profit at 19% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement

Statement of Standalone Unaudited Financial Results for the quarter ended 30 June 2018

₹ in Crore

Particulars	3 months ended			Year Ended
	30/06/2018	31/03/2018	30/06/2017	31/03/2018
	Unaudited	Refer Note 3	Unaudited	Audited
Income				
Revenue from operations	441.95	462.60	397.93	1,830.45
Other income	69.06	6.00	4.70	73.01
Total Income	511.01	468.60	402.63	1,903.46
Expenses				
Cost of materials consumed	88.21	113.22	93.80	375.43
Purchases of stock-in-trade	14.87	13.44	18.59	73.01
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(20.50)	(32.55)	(32.39)	(49.15)
Employee benefits expense	95.63	96.76	79.78	342.89
Finance costs	0.11	0.05	0.04	0.24
Depreciation and amortisation expense	16.56	15.92	12.93	57.14
Other expenses	122.77	156.32	128.08	541.46
Total Expenses	317.65	363.16	300.83	1,341.02
Profit before tax	193.36	105.44	101.80	562.44
Tax Expense				
Current Tax (net)	42.37	20.60	21.73	114.60
Deferred Tax (net)	0.17	6.34	3.34	20.32
Profit after tax	150.82	78.50	76.73	427.52
Other Comprehensive Income (OCI)				
Items that will not be reclassified subsequently to profit or loss	(0.50)	(1.86)	(0.04)	(1.99)
Income tax relating to Items that will be reclassified to profit or loss	0.17	0.65	0.01	0.69
Other Comprehensive Income for the year, net of tax	(0.33)	(1.21)	(0.03)	(1.30)
Total Comprehensive Income for the year	150.49	77.29	76.70	426.22
Paid-up Equity Share Capital (Face value of ₹ 2 each)	17.69	17.69	17.69	17.69
Other Equity				1,913.81
Earnings Per Share (Face value of ₹ 2 each)				
Basic - in ₹	17.14	8.92	8.72	48.59
Diluted - in ₹	17.13	8.92	8.72	48.58


Notes :

- The above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 31 July 2018.
- Statutory Auditors have carried out Limited Review of the financial results for the quarter ended 30 June 2018.
- The figures for the quarter ended March 31, 2018 are balancing figures between audited figures in respect of full financial year and unaudited published figures upto the third quarter.
- Other income includes :

	3 months ended			Year Ended
	30/06/2018	31/03/2018	30/06/2017	31/03/2018
Dividend from subsidiaries (₹ in Crore)	60.98	-	-	49.65

- During the quarter, 1,000 equity shares of ₹ 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by ₹ 2,000 and securities premium account by ₹ 0.12 crores.
- The Company operates exclusively in one reportable business segment i.e., "Pharmaceuticals".
- There are no exceptional items.
- Amalgamation of Gabs Investments Private Limited ('Gabs') with the Company was approved by Board of Directors on 18 March 2017 and by Shareholders of both Companies on 10 October 2017. Gabs holds 83,92,262 equity shares in the Company, representing about 9.54% of total paid up capital, against which Company will issue same number of shares to shareholders of Gabs. Amalgamation is subject to approval of regulatory authorities as prescribed in law. Hence, no effect of the same is given in financial statements.
- Effective 1 July 2017, sales are recorded net of GST whereas earlier sales were recorded gross of excise duty which formed part of expenses. Hence, revenue from operations for the three months ended 30 June 2018 are not comparable with previous period corresponding figures.

Mumbai, 31 July 2018


 By order of the Board
 For Ajanta Pharma Ltd.

 Yogesh M. Agrawal
 Managing Director